Smart Glasses vs. Retinal Implants: Can PRIMA Restore Sight in Macular Degeneration?
Independent health and technology research | Updated: October 2026
Imagine being unable to read a book, recognise a face or see the words on a computer screen because the central part of your retina has been irreversibly damaged. Now imagine recovering some of that lost central vision through a tiny electronic implant placed beneath the retina, paired with a specialised pair of glasses that sends visual information directly to the implant.
This is no longer entirely science fiction. Science Corporation's PRIMA (Photovoltaic Retina Implant Microarray) system has emerged as a major development in bionic vision. Unlike conventional low-vision glasses, which magnify or enhance images that the eyes can still perceive, PRIMA is designed to replace some of the lost light-sensing function of damaged retinal cells.
The system has demonstrated clinically meaningful improvements in visual acuity in people with severe central vision loss caused by geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). In July 2026, PRIMA received a CE mark, allowing commercial availability across 30 European countries.
However, this is not a complete cure for blindness, nor does it restore normal human eyesight. The current system produces limited monochromatic vision, has a relatively small visual field and requires specialised retinal surgery and rehabilitation.
So how does it compare with eSight electronic glasses, AI-powered smart glasses and other emerging bionic vision technologies? More importantly, who might qualify, and what can patients realistically expect to see?
- PRIMA is a retinal implant: A small photovoltaic chip is surgically placed beneath the retina and paired with specialised glasses.
- Its initial indication is specific: Severe central vision loss associated with geographic atrophy caused by AMD.
- Clinical evidence is encouraging: In the 38-person PRIMAvera study, 81% of the 32 participants assessed at 12 months achieved a clinically meaningful improvement in visual acuity.
- It does not restore normal vision: Current prosthetic vision is monochromatic, has limited resolution and covers a small central field.
- eSight works differently: It uses cameras and electronic displays to enhance residual vision without retinal surgery.
- Regulatory access differs by country: PRIMA received European CE marking in July 2026, while US FDA marketing authorisation remains a separate regulatory process.
- Understanding geographic atrophy and vision loss
- What is the PRIMA retinal implant?
- How does bionic vision work?
- Clinical evidence: What did the PRIMAvera trial show?
- Three-year results: Is restored vision durable?
- What can patients actually see?
- Who qualifies for a PRIMA retinal implant?
- PRIMA vs. eSight vs. smart glasses
- Other bionic vision technologies
- Regulatory status and availability in 2026
- Can patients access PRIMA in Malaysia?
- Risks, limitations and unanswered questions
- The future of vision restoration
- Frequently asked questions
1. Understanding geographic atrophy: Why does macular degeneration cause blindness?
The retina is a specialised layer of light-sensitive tissue at the back of the eye. It converts incoming light into electrical signals that travel through the optic nerve to the brain, where they are interpreted as vision.
The macula is the central region of the retina responsible for detailed vision. Its central area, called the fovea, provides the high-resolution vision required for reading, recognising faces and seeing fine details.
Age-related macular degeneration damages the macula and can progressively impair central vision.
Dry AMD and geographic atrophy
Geographic atrophy is an advanced form of dry AMD characterised by progressive loss of retinal cells, including photoreceptors, retinal pigment epithelium (RPE) and supporting structures.
Photoreceptors are the rods and cones responsible for detecting light. When these cells are destroyed, the affected retinal area can no longer convert incoming light into normal visual signals.
When geographic atrophy involves the fovea, patients can experience profound central vision loss. They may still retain some peripheral vision, but reading, recognising faces and performing detailed activities can become extremely difficult.
Importantly, geographic atrophy is different from wet AMD, which involves abnormal blood vessel growth and leakage beneath or within the retina. The two forms can sometimes coexist.
Conventional treatments and low-vision rehabilitation can help manage the disease and its consequences. Certain approved treatments for geographic atrophy aim to slow lesion enlargement in eligible patients, but they do not regenerate photoreceptors that have already been destroyed.
This is the biological problem PRIMA attempts to address: rather than regenerating the original photoreceptors, it introduces an electronic system that can stimulate surviving retinal neurons and transmit artificial visual information to the brain.
Further reading: American Academy of Ophthalmology – Geographic Atrophy and National Eye Institute – Age-Related Macular Degeneration.
Related OneDayMD topic: Macular Degeneration.
2. What is the PRIMA retinal implant?
PRIMA stands for Photovoltaic Retina Implant Microarray. It is a wireless subretinal prosthesis developed from research originally conducted at Stanford University and subsequently commercialised by Science Corporation.
The system combines two essential components:
1. A tiny photovoltaic retinal implant
The implant is approximately 2 × 2 mm in size and about 30 micrometres thick. It contains an array of 378 microscopic photovoltaic pixels, each approximately 100 micrometres wide.
The implant is surgically placed beneath the retina in the area affected by geographic atrophy.
2. Specialised glasses and an external processor
The patient wears specially designed glasses containing a camera and an infrared projection system. A processor converts visual information captured by the camera into a signal that is projected onto the implant using pulsed near-infrared light.
This allows the implant to receive visual information without requiring a conventional wired connection or an internal battery.
Traditional electronic glasses display an enhanced image that the user's remaining visual system must interpret. PRIMA instead converts the projected image into electrical stimulation at the retina, bypassing the need for the destroyed photoreceptors in the treated central area.
PRIMA is therefore better described as a retinal neuroprosthesis or bionic vision system rather than an ordinary pair of smart glasses.
3. How does PRIMA restore artificial vision?
The principle behind PRIMA is relatively straightforward, although the underlying engineering is sophisticated.
- Capture: A camera integrated into the specialised glasses captures an image of the patient's surroundings.
- Process: An external processor adjusts the image and converts it into a pattern of light signals.
- Project: The glasses project pulsed near-infrared light onto the photovoltaic retinal implant.
- Convert: The photovoltaic pixels convert the projected light into local electrical currents.
- Stimulate: These currents stimulate surviving retinal neurons, primarily bipolar cells.
- Transmit: The stimulated retinal circuitry passes signals through the remaining visual pathway, including the optic nerve, to the brain.
- Interpret: The brain learns to interpret the resulting artificial visual percepts through training and rehabilitation.
The crucial innovation is that PRIMA bypasses damaged photoreceptors while making use of surviving retinal circuitry.
The technology does not need to regenerate the original rods and cones. Instead, it provides an alternative way to introduce visual information into the nervous system.
This is particularly relevant in geographic atrophy, where substantial damage to the photoreceptors can occur while some of the deeper retinal neural circuitry remains capable of responding to stimulation.
Research describing the photovoltaic approach is available in Nature Communications – Simultaneous Perception of Prosthetic and Natural Vision in AMD Patients.
4. Clinical evidence: What did the PRIMAvera trial demonstrate?
The most important clinical evidence for PRIMA comes from the PRIMAvera study, a multicentre prospective clinical trial involving people with severe central vision loss due to geographic atrophy associated with AMD.
The pivotal results were published in the New England Journal of Medicine (NEJM), with online publication on 20 October 2025 and inclusion in the January 2026 issue.
PRIMAvera study: Key findings
- Participants implanted: 38.
- Study design: Open-label, prospective, multicentre, single-group study with baseline-controlled assessments.
- Clinical sites: 17 centres across five countries.
- Primary assessment: Visual acuity improvement at 12 months.
- Meaningful improvement: Defined as an improvement of at least 0.2 logMAR, equivalent to approximately 10 ETDRS letters.
Visual acuity outcomes at 12 months
26 of the 32 participants who completed the 12-month assessment achieved an improvement of at least 0.2 logMAR.
After statistical imputation for participants with missing follow-up data, researchers estimated that 80% of all 38 implanted participants would have achieved the primary endpoint.
27 of the 32 participants assessed at 12 months demonstrated the ability to read letters, numbers and words using prosthetic vision in their home environment.
These findings are significant because they demonstrate that the implant can provide more than a simple perception of light. Some participants recovered useful form vision, including the ability to identify and read visual characters.
What about natural peripheral vision?
One important finding was that the mean natural visual acuity in the implanted eye, assessed without the PRIMA glasses, remained equivalent to baseline at 12 months.
This suggests that implantation did not produce an average deterioration in the remaining natural vision measured in the trial during this period.
However, this should not be interpreted as proof that surgery carries no risk to residual sight. Individual surgical complications remain possible.
How should we interpret the results?
The findings are promising, particularly given the severity of vision loss among participants. Nevertheless, several important limitations should be considered:
- The study involved only 38 implanted participants.
- Only 32 participants completed the 12-month visual assessment.
- The trial was open-label and did not include a parallel untreated control group.
- The primary outcome measured improvement in prosthetic visual acuity rather than restoration of normal vision.
- Longer-term follow-up is necessary to establish durability, safety and real-world effectiveness.
The study was funded by Science Corporation and the Moorfields National Institute for Health and Care Research Biomedical Research Centre. Independent replication and larger real-world studies will remain important.
Primary clinical reference: Holz FG et al. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. New England Journal of Medicine. 2026;394:232–242.
Read the NEJM clinical study | View PubMed record | PRIMAvera trial registration.
5. Three-year results: Is restored vision durable?
An important development in October 2026 was the presentation of extended 36-month PRIMAvera follow-up findings.
At the 2026 American Academy of Ophthalmology meeting, investigators reported an average visual acuity improvement of approximately 30 ETDRS letters at 36 months.
The October 2026 reporting included the following findings:
- 38 patients had originally received the implant.
- 18 patients had available visual efficacy assessments at 36 months in the reported analysis.
- Approximately 30 ETDRS letters of mean visual acuity improvement were reported.
- 14 of the 18 patients assessed were reported to have achieved an improvement of at least 15 ETDRS letters in the extended follow-up reporting.
- Natural vision with the device switched off remained generally stable in the reported participants.
The longer-term findings are encouraging because they suggest that visual gains may persist beyond the original 12-month clinical assessment.
However, these results must be interpreted cautiously. The three-year visual outcome was available for only 18 of the original 38 implanted participants. The results were conference-reported in October 2026 and should not be treated as a completed peer-reviewed three-year publication.
It is also important to distinguish these extended results from the original 12-month NEJM study. The two datasets have different follow-up populations and should not be combined as though all 38 participants had three-year visual assessments.
Sources:
- Retinal Physician – Assessing PRIMA's Efficacy and Safety at 36 Months.
- Inside BCI – PRIMA's Three-Year Vision Results.
6. What can patients actually see with PRIMA?
This is perhaps the most important question for patients and their families.
The phrase "restore vision" can easily create unrealistic expectations. PRIMA provides artificial visual perception, not normal biological vision.
What patients may be able to do
- Recognise and distinguish letters.
- Read certain printed words and numbers.
- Identify enlarged visual characters.
- Perceive patterns and visual shapes.
- Perform selected reading and visual tasks after rehabilitation.
- Combine restored central prosthetic vision with remaining natural peripheral vision.
What PRIMA does not currently restore
- Normal 20/20 visual acuity.
- Natural full-colour vision.
- A normal visual field.
- Full-resolution facial recognition.
- Natural depth perception in every situation.
- Normal night vision.
- Normal driving vision or automatic eligibility to drive.
- All the complex visual abilities of a healthy retina.
Is PRIMA vision black and white?
The current system produces monochromatic or grayscale artificial vision rather than natural full-colour vision.
The implant contains a relatively small number of photovoltaic pixels. Consequently, spatial resolution and contrast sensitivity are limited compared with natural human vision.
The system can also magnify images electronically. However, increasing magnification comes at the cost of reducing the effective field of view: the patient sees a larger representation of a smaller part of the original image.
Can PRIMA help people recognise faces?
Face recognition remains a challenging task for current prosthetic vision systems.
A 2026 research publication in the Journal of NeuroEngineering and Rehabilitation examined the limited spatial resolution and contrast sensitivity of PRIMA-like prosthetic vision. The researchers reported that machine-learning-based facial feature enhancement and contrast adjustments could improve simulated face representation.
This is an interesting development, but the proposed image-processing techniques should not be confused with an established clinical feature that reliably restores natural face recognition in patients.
Reference: Simulation of Prosthetic Vision with the PRIMA System and Enhancement of Face Representation.
7. Who qualifies for a PRIMA retinal implant?
PRIMA is not intended for every person with poor eyesight or every patient with macular degeneration.
Its current European indication is focused on people with severe visual impairment associated with geographic atrophy secondary to age-related macular degeneration.
Who was eligible for the pivotal clinical trial?
The PRIMAvera clinical study used specific inclusion criteria, including:
- Age: 60 years or older.
- Diagnosis: Confirmed geographic atrophy due to AMD in both eyes.
- Visual acuity: Best-corrected visual acuity of 1.2 logMAR or worse (approximately 20/320 or worse) in the study eye.
- Retinal damage: An atrophic lesion involving the fovea, with an area greater than 4.5 mm² and a minimum diameter greater than 2.4 mm.
These are the inclusion criteria used in the clinical trial. They should not automatically be interpreted as the complete current commercial eligibility criteria in every country.
Why must some retinal cells remain functional?
PRIMA bypasses damaged photoreceptors. It does not bypass the entire visual system.
The technology depends on surviving retinal neurons and an adequately functioning downstream visual pathway, including the optic nerve and brain regions responsible for processing visual signals.
Consequently, patients with extensive damage beyond the photoreceptors may not receive the same benefit.
Who may not be suitable?
Potential limitations include:
- Retinal conditions outside the device's approved indication.
- Extensive damage to the inner retinal layers or optic nerve.
- Other significant eye diseases that limit the ability to obtain useful vision.
- Ocular or general medical conditions that make surgery unsuitable.
- Difficulty undertaking rehabilitation, using the specialised equipment or attending follow-up appointments.
The presence of wet AMD, glaucoma, diabetic retinopathy or another eye disease requires individual assessment. These conditions should not be presented as established PRIMA treatment indications.
How is eligibility assessed?
A retinal specialist would generally need to assess:
- Detailed eye examination and visual acuity.
- Optical coherence tomography (OCT) and retinal imaging.
- Location, size and extent of geographic atrophy.
- Condition of the remaining retinal layers.
- Optic nerve and other visual pathway function.
- Previous eye surgery and suitability for vitreoretinal surgery.
- Ability to undertake postoperative rehabilitation.
Patients should not assume they qualify solely because they have advanced dry AMD. A specialist assessment is essential.
Clinical eligibility details: ClinicalTrials.gov – NCT04676854.
8. PRIMA vs. eSight vs. smart glasses: What is the difference?
Although these technologies may all be described as smart glasses or vision-enhancement devices, they have fundamentally different purposes.
PRIMA: Replace some lost retinal function
Purpose: Bypass destroyed photoreceptors and stimulate surviving retinal neurons.
Target population: Selected patients with severe central vision loss due to geographic atrophy from AMD.
Surgery: Yes. Requires subretinal implantation.
Type of vision: Artificial monochromatic central vision with limited resolution.
Main advantage: Can provide form vision even when central photoreceptors have been destroyed.
Main limitation: Invasive surgery, limited visual field, restricted resolution and specific eligibility requirements.
eSight: Enhance residual vision electronically
Purpose: Capture and digitally enhance visual information before displaying it to the user.
Target population: Selected people with low vision who can benefit from electronic image enhancement.
Surgery: No.
Type of vision: Magnified and digitally enhanced image display.
Main advantage: Non-invasive, adjustable magnification, contrast enhancement and colour filtering.
Main limitation: It does not replace destroyed retinal photoreceptors or electrically stimulate the retina.
The current eSight Go system uses a high-definition camera to capture video and displays processed images on two OLED screens positioned near the eyes.
According to the manufacturer's published specifications, eSight Go includes:
- 12-megapixel camera.
- Magnification of up to 24×.
- Full HD 1920 × 1080 OLED displays.
- Approximately 45-degree display field of view.
- Image stabilisation and autofocus.
- Contrast adjustment and colour filters.
- Wireless connectivity and mobile application support.
These are manufacturer specifications, not a guarantee of clinical outcomes for every user. The usefulness of an electronic low-vision device depends on the person's underlying eye condition, remaining vision and ability to interpret the displayed image.
Official product information: eSight – How It Works.
AI-powered smart glasses: Provide information rather than restore sight
Purpose: Help users interpret their surroundings through object recognition, text reading, navigation and voice assistance.
Surgery: No.
Type of assistance: Digital information, spoken descriptions and contextual guidance.
Main advantage: Can assist users with substantial visual impairment, including some who have very limited usable sight.
Main limitation: Does not regenerate retinal cells or restore biological vision.
An AI assistant may tell a person what an object is, read a restaurant menu aloud or describe the surroundings. This can improve independence without actually restoring sight.
Side-by-side comparison
| Feature | PRIMA | eSight Go | AI Smart Glasses |
|---|---|---|---|
| Technology | Retinal implant and glasses | Camera and OLED displays | Camera and AI software |
| Surgery required | Yes | No | No |
| Primary function | Bypass damaged photoreceptors | Enhance residual vision | Interpret surroundings |
| Restores visual perception | Yes, artificial central vision | No, enhances available vision | No, primarily provides information |
| Intended use | Specific severe GA-related vision loss | Selected low-vision conditions | Accessibility and assistance |
| Normal colour vision | No | Depends on residual vision and display | Not applicable to audio descriptions |
| Rehabilitation | Essential | Training recommended | User training may help |
Editorial takeaway: PRIMA and eSight should not be viewed as direct competitors. They address different stages and mechanisms of vision impairment. PRIMA attempts to replace some lost retinal function, while eSight enhances images that can still be interpreted by the user's visual system.
9. Other bionic vision technologies: What is coming next?
PRIMA is part of a broader field of research into technologies that can restore or substitute for lost visual function.
1. Retinal prostheses
Retinal prostheses use electrical stimulation to activate surviving retinal neurons.
PRIMA is a subretinal photovoltaic approach. Other retinal implant designs use different electrode locations, materials and stimulation architectures.
These technologies have historically faced challenges involving resolution, durability, surgical complexity and the quality of artificial vision.
2. Cortical visual implants
Cortical implants take a different approach. Rather than stimulating retinal cells, they aim to stimulate areas of the brain's visual cortex directly.
The objective is to provide artificial visual sensations to people whose eyes or optic nerves may no longer transmit useful visual signals.
Such systems remain experimental and face substantial challenges involving electrode density, safety, long-term stability and the complexity of visual perception.
3. Optogenetics
Optogenetics involves introducing light-sensitive proteins into surviving retinal cells, potentially allowing cells that are not normally photoreceptors to respond to light.
This is a different biological approach from PRIMA's electronic stimulation. Clinical translation remains dependent on disease type, the specific intervention and the level of evidence available.
4. Gene therapy
Gene therapy seeks to correct or compensate for genetic defects responsible for certain inherited retinal diseases.
Some gene therapies are already established for specific genetic retinal conditions, but they should not be confused with treatments for age-related geographic atrophy.
5. Stem-cell and retinal regeneration research
Stem-cell approaches aim to replace or support damaged retinal cells, including retinal pigment epithelial cells and potentially photoreceptors.
However, replacing cells is only one part of the challenge. Researchers must also establish appropriate cellular integration, functional connections, long-term survival and meaningful visual improvement.
These approaches remain distinct from PRIMA and should not be promoted as proven cures for AMD.
10. PRIMA regulatory status and commercial availability in 2026
Regulatory authorisation is one of the most important developments in the PRIMA story.
Europe: CE mark received in July 2026
Science Corporation announced the European commercial launch of PRIMA on 22 July 2026.
The device received a CE mark under the European Union Medical Device Regulation from DEKRA, authorising commercial availability across 30 European countries.
This is a major milestone because PRIMA became the first brain-computer-interface device to receive CE marking for restoration of form vision, including the ability to read letters, numbers and words.
However, regulatory authorisation and widespread patient access are not the same thing.
Country-specific reimbursement applications and specialist clinical site activation are separate processes. An October 19, 2026 announcement from McDermott described negotiations concerning the first commercial PRIMA implantation at University Hospital Schleswig-Holstein in Lübeck, Germany.
This illustrates that a device can be commercially authorised while practical access is still being established.
Sources: Science Corporation – European CE Mark Announcement | McDermott – First Commercial Implant Negotiations, October 2026.
United States: FDA Breakthrough Device and Humanitarian Use Device designations
PRIMA has received:
- FDA Breakthrough Device designation.
- Humanitarian Use Device designations covering specified rare-disease indications, including advanced geographic atrophy and Stargardt disease.
These are important regulatory milestones, but they do not mean that PRIMA has received full FDA marketing authorisation.
The distinctions are important:
- Breakthrough Device designation: Provides an opportunity for more intensive interaction with the FDA and an expedited development and review process for eligible devices. It is not marketing approval.
- Humanitarian Use Device (HUD) designation: Identifies a device intended for a rare condition or population. It is not the same as authorisation to market the product.
- Humanitarian Device Exemption (HDE): A separate regulatory application and authorisation route that may permit marketing of a HUD under specified conditions.
An HDE also has a different evidentiary framework from conventional Premarket Approval (PMA). The FDA explains that an approved HDE does not require the same demonstration of effectiveness as a PMA, and its labelling must state that effectiveness for the specific indication has not been demonstrated.
As of 31 October 2026, available public reporting describes PRIMA as still pursuing US marketing authorisation. A Breakthrough or HUD designation must not be represented as FDA approval.
Official references:
United Kingdom and other international markets
A European CE mark should not automatically be interpreted as an identical regulatory authorisation in every country outside the EU framework.
Availability in the United Kingdom, Switzerland, Australia, Singapore and other markets depends on applicable local rules, commercial distribution and healthcare-system arrangements.
11. Risks, limitations and unanswered questions
A retinal implant is not a simple wearable device. It requires intraocular surgery, and the risks need to be considered carefully.
1. Surgical complications
PRIMA implantation involves vitreoretinal surgery, including a subretinal approach. Potential complications include:
- Retinal breaks or retinal detachment.
- Subretinal haemorrhage.
- Macular hole.
- Elevated intraocular pressure.
- Proliferative vitreoretinopathy.
- Other complications associated with intraocular surgery.
In the original PRIMAvera 12-month report, 26 serious adverse events were recorded in 19 participants. Twenty-one of these events occurred within two months after surgery, and 20 of those 21 events resolved within two months of onset.
The study included four severe events: macular hole, ocular hypertension, retinal detachment and proliferative vitreoretinopathy.
The investigators reported that these serious events were associated with the surgical procedure alone or with the procedure and device together; no serious adverse event was attributed to the device alone.
Although many events resolved, these findings should not be used to minimise the potential risks of surgery.
2. Limited visual resolution
The current implant contains only 378 pixels. This is substantially less than the resolution of a normal human retina.
Improvements in pixel density, contrast processing and image reconstruction may eventually improve reading, object recognition and more complex visual tasks.
3. Restricted visual field
The implant covers a small retinal area. Its physical dimensions correspond to approximately seven degrees of visual angle.
Consequently, the artificial central visual field is limited compared with normal vision. The external glasses can magnify visual information, but magnification reduces the portion of the scene represented on the implant.
4. Rehabilitation requirements
Patients must learn how to operate the system and interpret the artificial visual information. Visual training, scanning techniques and adaptation are important parts of the treatment process.
5. Long-term durability and performance
The October 2026 three-year results are encouraging, but larger follow-up datasets are needed to establish how consistently the benefits persist over longer periods.
Future studies should also examine:
- Five-year and longer-term implant stability.
- Long-term retinal tissue responses.
- Real-world reading and mobility outcomes.
- Quality of life and patient independence.
- Long-term surgical complication rates.
- Cost-effectiveness and healthcare reimbursement.
12. The future of bionic vision: Where is the technology heading?
PRIMA represents an important transition in vision technology. For decades, most visual aids have concentrated on magnifying existing images, improving contrast or converting visual information into audio.
Retinal neuroprostheses introduce a different possibility: directly replacing some of the function lost when retinal cells are destroyed.
Several developments could further improve this approach.
Higher-resolution implants
More densely packed photovoltaic pixels could potentially improve the ability to distinguish small letters, shapes and other visual details.
AI-powered image processing
Artificial intelligence could help simplify complex scenes, emphasise important features, improve contrast and make objects easier to identify before the information is projected onto the implant.
Better visual-field coverage
Future implants may attempt to cover a larger retinal area while maintaining suitable surgical safety and electrical stimulation.
Improved rehabilitation
AI-assisted training systems and personalised image-processing settings may help patients adapt to prosthetic vision more efficiently.
Integration with other assistive technologies
Retinal implants may eventually work alongside speech recognition, navigation systems, environmental sensors and AI-powered wearable devices.
This could produce a more comprehensive assistive ecosystem in which artificial retinal vision is combined with audio information and intelligent environmental interpretation.
However, these developments remain areas for research and development. Improved future performance should not be confused with capabilities already demonstrated by the current commercial system.
13. Which technology is appropriate for different types of vision impairment?
There is no single technology that is best for every person with visual impairment. The appropriate approach depends on the underlying disease, the extent of retinal damage and the amount of useful vision remaining.
PRIMA may be worth discussing with a specialist if the patient's retinal anatomy and clinical characteristics match the device's intended indication.
Electronic magnifiers, eSight-type glasses, telescopic devices and other low-vision aids may be appropriate. The patient should ideally trial the device under professional guidance.
AI-powered audio assistants, screen readers, text-to-speech systems and navigation devices may help with daily activities without attempting to restore visual perception.
Depending on the specific diagnosis, specialist evaluation may include approved gene therapies, clinical trials, optogenetic research or other emerging interventions. PRIMA's AMD indication should not be assumed to apply.
A comprehensive low-vision assessment remains essential. A retinal implant, electronic glasses and AI assistant may also serve complementary rather than mutually exclusive roles.
14. Frequently asked questions
Can PRIMA restore eyesight in people with macular degeneration?
PRIMA has demonstrated the ability to restore a limited form of artificial central vision in selected patients with severe geographic atrophy caused by AMD. Clinical trial participants were able to read certain letters, numbers and words. It does not restore normal eyesight or regenerate damaged photoreceptors.
Is PRIMA a bionic eye?
PRIMA can reasonably be described as a bionic vision system or retinal neuroprosthesis. It consists of an implanted photovoltaic chip, specialised glasses and an image-processing system that together provide artificial visual stimulation.
Does PRIMA restore colour vision?
No. The current PRIMA system produces monochromatic or grayscale artificial vision rather than natural full-colour perception.
Can people with geographic atrophy read again after PRIMA implantation?
Some patients have demonstrated the ability to read letters, numbers and words using prosthetic vision. In the PRIMAvera study, 27 of the 32 participants assessed at 12 months could read these visual characters at home. Individual outcomes vary.
Can PRIMA restore facial recognition?
Facial recognition remains challenging because of the implant's limited spatial resolution and contrast sensitivity. Research into AI-assisted image processing may improve facial feature representation, but reliable natural face recognition has not been established as a clinical outcome.
Is PRIMA better than eSight glasses?
They are designed for different purposes. PRIMA attempts to replace some lost retinal function by stimulating surviving retinal neurons. eSight enhances images electronically for people who retain visual pathways that can benefit from the displayed information. Neither should be considered universally better.
Can eSight help someone who has completely lost central vision?
Some people with severe central vision loss may benefit from electronic low-vision devices, depending on their remaining visual function. However, an electronic display cannot replace destroyed retinal cells. A professional assessment and hands-on trial are important before purchasing.
Is PRIMA approved by the FDA?
As of 31 October 2026, PRIMA has received FDA Breakthrough Device and Humanitarian Use Device designations. These are not equivalent to FDA marketing authorisation. The US regulatory pathway must be completed separately.
Is PRIMA available in Europe?
Yes. PRIMA received a CE mark in July 2026, authorising commercial availability across 30 European countries. Actual access depends on specialist centres, country-specific implementation and reimbursement.
Does PRIMA cure macular degeneration?
No. PRIMA is a visual neuroprosthesis designed to provide artificial central vision in selected patients. It does not cure AMD, stop the underlying disease or regenerate the original photoreceptors.
Can patients drive after receiving PRIMA?
There is no basis for assuming that PRIMA restores the visual acuity, field of vision or other visual functions required for driving. Patients must comply with local driving regulations and obtain an appropriate professional assessment.
15. Conclusion: From vision enhancement to vision restoration
The development of PRIMA represents a meaningful milestone in the treatment of severe vision loss caused by geographic atrophy.
For the first time, a commercially CE-marked retinal neuroprosthesis is attempting to restore useful central visual perception in people whose photoreceptors have been irreversibly destroyed by advanced AMD.
The clinical evidence is encouraging. The PRIMAvera trial demonstrated meaningful improvements in visual acuity, and some participants regained the ability to read letters, numbers and words. Early three-year follow-up findings presented in October 2026 suggest that visual gains may be maintained over time, although larger and peer-reviewed long-term datasets remain necessary.
Nevertheless, important limitations remain. PRIMA does not restore normal colour vision, natural visual acuity or a full visual field. It requires surgery, specialised glasses and rehabilitation, and its current indication is restricted to a specific group of patients.
The distinction between different vision technologies is therefore essential:
- eSight and electronic low-vision glasses: Enhance available visual information.
- AI smart glasses: Interpret the environment and provide digital or spoken assistance.
- PRIMA and retinal implants: Attempt to replace some lost retinal function and produce artificial visual perception.
- Gene therapy, optogenetics and regenerative medicine: Explore biological approaches to restoring or replacing damaged visual cells and pathways.
These approaches represent different but potentially complementary directions in assistive technology and vision restoration.
The larger opportunity is not simply to develop better glasses. It is to understand how technology, neuroscience, artificial intelligence and regenerative medicine can work together to restore independence and improve quality of life for people living with blindness and severe visual impairment.
PRIMA should be viewed as an important early commercial milestone in bionic vision, not as a cure for blindness. Its real significance is that it moves retinal neuroprostheses beyond experimental demonstrations towards regulated clinical use. The next challenge is to establish long-term safety, meaningful everyday functional benefits, affordability and access beyond specialist European centres.
References and Further Reading
The following sources provide the clinical, regulatory and technical evidence underlying this article. Manufacturer specifications and commercial announcements are identified separately from peer-reviewed clinical research.
-
Holz FG et al. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. New England Journal of Medicine. 2026;394:232–242.
https://doi.org/10.1056/NEJMoa2501396 -
ClinicalTrials.gov. NCT04676854 – Restoration of Central Vision with the PRIMA System in Patients with Atrophic AMD.
Clinical trial details and eligibility criteria -
Science Corporation. PRIMA – Photovoltaic Retina Implant Microarray.
Official PRIMA technology information -
Science Corporation. European Commercial Launch and CE Mark Announcement, 22 July 2026.
Official company announcement -
McDermott Will & Schulte. Negotiations regarding the first commercial PRIMA implant in Europe, 19 October 2026.
Commercial implementation update -
US Food and Drug Administration. Breakthrough Devices Program.
FDA regulatory guidance -
US Food and Drug Administration. Humanitarian Device Exemption Approvals.
FDA HDE regulatory requirements -
Kochnev Goldstein A et al. Simulation of Prosthetic Vision with the PRIMA System and Enhancement of Face Representation. Journal of NeuroEngineering and Rehabilitation. 2026.
Research paper -
Nature Communications. Simultaneous Perception of Prosthetic and Natural Vision in AMD Patients. 2022.
Technical research -
eSight Eyewear. How eSight Go Works.
Manufacturer technology and specifications -
American Academy of Ophthalmology. Geographic Atrophy.
Clinical background -
National Eye Institute. Age-Related Macular Degeneration.
AMD overview
Medical Disclaimer
This article is for educational and informational purposes only. It is not a substitute for individual medical advice, diagnosis or treatment. PRIMA is a specialised retinal implant with specific clinical indications and surgical risks. Patients with geographic atrophy, macular degeneration or other vision disorders should consult a qualified ophthalmologist or vitreoretinal specialist to discuss appropriate treatment options. Regulatory approval, availability and reimbursement vary by country and may change over time.
OneDayMD is an independent health research and education platform. We aim to distinguish established clinical evidence, emerging technologies, manufacturer claims and experimental research. We do not provide individual medical treatment recommendations.
.png)
.png)
.png)
.png)
Comments
Post a Comment